14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BHVN vs RARE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Biohaven Ltd. (BHVN) captures the overall head-to-head institutional edge over Ultragenyx Pharmaceutical Inc. (RARE) on higher Unified Composite conviction (42.1/100 HOLD vs. 43.8/100 HOLD) after splitting the core matrix 4–5 (led by Profitability & Quality, Options & Positioning), while RARE wins 4–2 across the 6-pillar growth and valuation breakdown. BHVN trades at $13.90 (N/M Forward P/E, 0.0% operating margin) versus RARE at $15.96 (11.2x Forward P/E, -59.9% operating margin).
Composite vs. Pillar Nuance: While RARE currently prints a higher short-term Unified Composite Score (43.8/100 HOLD vs. BHVN 42.1/100 HOLD), BHVN captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -59.9% operating margin) and revenue trajectory (+0.0% vs. +8.1% YoY).
Technical & Structure Timing Caution: BHVN is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4); meanwhile RARE is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHVN vs RARE. Trailing 12-month operating profitability (BHVN 0.0% vs RARE -59.9%) and valuation multiples (BHVN N/M vs RARE 11.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.7B market capitalization and -59.9% operating margin.
OpEx & R&D Reinvestment49.2% of Rev ($359M)
90D Engineering Disclosures0 Published
Investor FAQ BHVN vs RARE Key Questions & Quantitative Answers
As of Nov 16, 2026, Biohaven Ltd. (BHVN) captures the overall head-to-head institutional edge over Ultragenyx Pharmaceutical Inc. (RARE) on higher Unified Composite conviction (42.1/100 HOLD vs. 43.8/100 HOLD) after splitting the core matrix 4–5 (led by Profitability & Quality, Options & Positioning), while RARE wins 4–2 across the 6-pillar growth and valuation breakdown. BHVN trades at $13.90 (N/M Forward P/E, 0.0% operating margin) versus RARE at $15.96 (11.2x Forward P/E, -59.9% operating margin). Composite vs. Pillar Nuance: While RARE currently prints a higher short-term Unified Composite Score (43.8/100 HOLD vs. BHVN 42.1/100 HOLD), BHVN captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -59.9% operating margin) and revenue trajectory (+0.0% vs. +8.1% YoY). Technical & Structure Timing Caution: BHVN is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4); meanwhile RARE is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
RARE leads the Growth & Scale pillar: BHVN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with RARE at +8.1% YoY revenue growth and +0.0% YoY earnings growth on $730M TTM revenue (-10.7% gross margin, -59.9% operating margin). On trailing 12-month operating scale, BHVN generates N/A in USD-normalized revenue versus $730M for RARE. In operating R&D and SG&A reinvestment, BHVN deploys N/A (0 90-day corporate R&D disclosures) versus 49.2% of Rev ($359M) (0 disclosures) for RARE.
RARE screens cheaper on headline valuation multiples. BHVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas RARE trades at 11.2x Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-61.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BHVN (-799.5% ROE) versus RARE (-608.5% ROE) capital efficiency.
In options market volatility and institutional positioning, BHVN carries 91.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.41β · 111% Vol realized risk). By comparison, RARE carries 171.9% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.40x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.41β · 58% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.